Skip to NavigationSkip to content

health economics and outcomes research

Redefining the value of medicines with patients at the centre

Published on 04/11/19 at 12:11pm

Liz Lewis, Head of Global Oncology Patient Value, Policy and Access at Takeda Oncology, discusses the importance and challenges of making the patient voice heard in the process of determining the value of drugs.

Damage control: How will pharma manage the health economic impacts of Brexit?

Published on 23/10/19 at 11:00am

When it comes to life sciences and patient outcomes, the UK’s destiny is inextricably tied to its relationship with the EU. With services already stretched to breaking point and key patients already unable to access the crucial medicines they need, how will the UK’s health economics be hit by an incoming Brexit?

The economics of mental health

Published on 08/10/18 at 12:01pm

Louis Goss examines mental health from a health economics and outcomes research (HEOR) perspective and asks what might be done to improve the way in which we treat medical as well as societal problems related to these conditions.

Mental health issues have been estimated to cost the world economy $2.5 trillion each year. To put that into perspective, the United Kingdom’s gross domestic product (GDP) was $2.6 trillion in 2017, while the world’s economy was estimated to be worth $78.28 trillion in 2014.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches